COSCIENS Biopharma Inc
TSX:CSCI

Watchlist Manager
COSCIENS Biopharma Inc Logo
COSCIENS Biopharma Inc
TSX:CSCI
Watchlist
Price: 2.86 CAD Market Closed
Market Cap: 9.3m CAD

COSCIENS Biopharma Inc
Other Current Assets

Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Quarterly
Annual
|
See Also

COSCIENS Biopharma Inc
Other Current Assets Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Other Current Assets CAGR 3Y CAGR 5Y CAGR 10Y
COSCIENS Biopharma Inc
TSX:CSCI
Other Current Assets
$1.9m
CAGR 3-Years
-8%
CAGR 5-Years
37%
CAGR 10-Years
21%
Theratechnologies Inc
TSX:TH
Other Current Assets
$4.1m
CAGR 3-Years
-20%
CAGR 5-Years
3%
CAGR 10-Years
13%
Repare Therapeutics Inc
NASDAQ:RPTX
Other Current Assets
$3.5m
CAGR 3-Years
-14%
CAGR 5-Years
-16%
CAGR 10-Years
N/A
Aurinia Pharmaceuticals Inc
NASDAQ:AUPH
Other Current Assets
$11.7m
CAGR 3-Years
-10%
CAGR 5-Years
0%
CAGR 10-Years
31%
X
Xenon Pharmaceuticals Inc
NASDAQ:XENE
Other Current Assets
$17.1m
CAGR 3-Years
26%
CAGR 5-Years
49%
CAGR 10-Years
46%
Spectral Medical Inc
TSX:EDT
Other Current Assets
CA$711k
CAGR 3-Years
-4%
CAGR 5-Years
12%
CAGR 10-Years
4%
No Stocks Found

COSCIENS Biopharma Inc
Glance View

Market Cap
9.1m CAD
Industry
Biotechnology

COSCIENS Biopharma Inc is a CA-based company operating in Biotechnology industry. The company is headquartered in Toronto, Ontario. COSCIENS Biopharma Inc., formerly Aeterna Zentaris Inc., is a specialty biopharmaceutical company engaged in the development and commercialization of a diverse portfolio of pharmaceutical and diagnostic products, including those focused on areas of unmet medical need. Its lead product, macimorelin (Macrilen; Ghryvelin), is an oral test indicated for the diagnosis of adult growth hormone deficiency (AGHD). The firm is also engaged in the development of therapeutic assets and proprietary extraction technology, which is applied to the production of active ingredients from renewable plant resources used in cosmeceutical products (i.e., oat beta glucan and avenanthramides, which are found in skincare product brands like Aveeno and Burt’s Bees formulations) and being developed as potential nutraceuticals and/or pharmaceuticals.

CSCI Intrinsic Value
7.08 CAD
Undervaluation 60%
Intrinsic Value
Price

See Also

What is COSCIENS Biopharma Inc's Other Current Assets?
Other Current Assets
1.9m USD

Based on the financial report for Sep 30, 2025, COSCIENS Biopharma Inc's Other Current Assets amounts to 1.9m USD.

What is COSCIENS Biopharma Inc's Other Current Assets growth rate?
Other Current Assets CAGR 10Y
21%

Over the last year, the Other Current Assets growth was -33%. The average annual Other Current Assets growth rates for COSCIENS Biopharma Inc have been -8% over the past three years , 37% over the past five years , and 21% over the past ten years .

Back to Top